Klivira
Request demo

Optimizing Pediatric Oncology Availity Integration for Critical Therapies

Klivira's platform enhances pediatric oncology Availity integration, ensuring rapid prior authorization for life-saving treatments in a high-stakes environment.

For revenue cycle directors and prior authorization coordinators in pediatric oncology, navigating the complexities of payer requirements for specialized treatments can significantly impact patient care timelines. Integrating with Availity, a primary multi-payer clearinghouse, is crucial for submitting PAs efficiently, especially for high-cost and time-sensitive therapies.

The Unique PA Landscape in Pediatric Oncology

Pediatric oncology presents distinct prior authorization challenges due to specialized protocols, high-cost therapies, and the urgency of treatment initiation. From complex chemotherapy regimens guided by Children's Oncology Group (COG) protocols to advanced modalities like CAR-T cell therapy and proton beam radiation, each requires meticulous documentation and swift payer approval.

High-Volume Pediatric Oncology PA Triggers via Availity

  • **Chemotherapy Regimens:** Often multi-agent, protocol-driven (e.g., COG), requiring detailed treatment plans and supporting clinical evidence.
  • **CAR-T Cell Therapies:** Extremely high-cost, complex biologics necessitating extensive clinical justification, often involving specific NCCN guidelines.
  • **Proton Beam Therapy:** Advanced radiation oncology requiring detailed treatment planning, imaging, and justification against conventional radiation.
  • **Advanced Diagnostic Imaging:** PET/CT, specialized MRI sequences for staging and monitoring, requiring specific clinical indications.
  • **Investigational Drugs/Clinical Trials:** While some are exempt, many require PA for supportive care or off-label use.

Streamlining EMR-to-Payer Workflows with Availity

Effective prior authorization in pediatric oncology relies on seamless data flow from the EMR to the payer. Klivira's integration facilitates the extraction of necessary clinical data, such as oncology-specific progress notes, pathology reports, genetic testing results, and treatment plans, directly from your EMR. This data is then structured for submission through Availity, automating what would otherwise be a manual, time-consuming process across various payer portals.

Leveraging Clinical Guidelines for Robust Submissions

Prior authorizations for pediatric oncology treatments often require alignment with established clinical guidelines. Klivira's platform helps ensure that submissions through Availity incorporate references to relevant bodies like NCCN (National Comprehensive Cancer Network), ASCO (American Society of Clinical Oncology), and COG protocols. This evidence-based approach strengthens the PA request and reduces the likelihood of denials for medical necessity.

Klivira's Impact on Pediatric Oncology PA through Availity

By automating the prior authorization process and integrating directly with Availity, Klivira reduces administrative burden, accelerates approval times, and minimizes delays in critical pediatric cancer treatments. Our platform ensures that the comprehensive clinical documentation required for therapies like CAR-T and proton beam is accurately and efficiently transmitted to commercial payers via Availity Essentials.

Frequently asked questions

How does Klivira handle specific COG protocol requirements for PA via Availity?

Klivira's platform is configured to identify and extract the specific clinical data points and documentation required for COG protocols from your EMR. This information is then compiled and structured for submission through Availity, ensuring all necessary details for these complex chemotherapy regimens are included for payer review.

Can Klivira automate PA for CAR-T cell therapy through Availity?

Yes, Klivira automates the prior authorization process for CAR-T cell therapies. Our system extracts the extensive clinical documentation, including genetic testing, pathology reports, and treatment plans, from your EMR. This is then formatted and submitted to commercial payers via Availity Essentials, streamlining a traditionally labor-intensive PA.

What EMR data does Klivira use for pediatric oncology PAs submitted via Availity?

Klivira leverages a wide range of EMR data for pediatric oncology PAs, including physician orders (e.g., chemotherapy, radiation), progress notes, pathology reports, genetic testing results, imaging reports, and treatment plans. This data is securely extracted and used to build comprehensive PA requests for submission through Availity.

Does Klivira support X12 278 submissions to payers via Availity?

Klivira's platform is designed to support various electronic prior authorization (ePA) methods, including the X12 278 transaction set. When integrated with Availity, our system can facilitate the electronic submission of PA requests to payers that support this standard, optimizing the communication workflow.

How does Klivira ensure compliance with HIPAA when integrating with Availity for PHI?

Klivira adheres to stringent HIPAA compliance standards for handling PHI. Our integration with Availity employs secure, encrypted channels for data transmission, and access controls are meticulously managed. We operate as a Business Associate, ensuring all data handling practices align with regulatory requirements; discuss specifics with your compliance team.

Related coverage

Other pediatric-oncology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo